Prolyl hydroxylase domain 3 influences the radiotherapy efficacy of pancreatic cancer cells by targeting hypoxia-inducible factor-1α

PURPOSE: Pancreatic cancer is characterized by a hypoxic microenvironment and resistance to most currently available treatment modalities. Prolyl hydroxylase domain 3 (PHD3) is a rate-limiting enzyme that regulates the degradation of hypoxia-inducible factors (HIFs) and is deregulated in pancreatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Li-rui, Wu, Jun-xin, Cai, Shao-li, Huang, Yun-xia, Zhang, Xue-qing, Fu, Wan-kai, Zhuang, Qing-yang, Li, Jin-luan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278705/
https://www.ncbi.nlm.nih.gov/pubmed/30555241
http://dx.doi.org/10.2147/OTT.S187615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278705/
https://www.ncbi.nlm.nih.gov/pubmed/30555241
http://dx.doi.org/10.2147/OTT.S187615

Ejemplares similares